Table 4 outlines clinical and experimental findings, indicating that the apelinergic system modulates electrophysiology and conduction, linking altered apelin or ELABELA levels with atrial fibrillation, conduction disorders, and arrhythmia recurrence, thus suggesting anti-arrhythmic potential. Here, APLN is linked to atrial fibrillation.